Role of hyperbaric oxygen therapy in oral submucous fibrosis: a randomized comparative study from India
- Author:
Rukmini SAH
1
;
Vibha SINGH
;
Uma Shanker PAL
;
Shadab MOHAMMAD
;
Vijay KUMAR
;
Veerendra VERMA
;
Amiya AGRAWAL
;
Sandhya PANDEY
;
Ranjana SINGH
Author Information
- Publication Type:Original Article
- From:Archives of Craniofacial Surgery 2026;27(1):10-17
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:To assess the effectiveness of hyperbaric oxygen therapy (HBOT) as an adjunct to standard treatment in early-stage oral submucous fibrosis (OSMF), focusing on mouth opening, burning sensation, pain, and systemic inflammation.
Methods:A randomized comparative study was conducted on early-stage OSMF patients divided into two groups. Group 1 received HBOT along with intralesional triamcinolone, hyaluronidase, and oral antioxidants. Group 2 received only the standard intralesional therapy with antioxidants. Clinical parameters—interincisal distance, burning sensation, and pain—were recorded at baseline, first, and second followup. Serum C-reactive protein (CRP) levels were measured pre- and post-treatment. Statistical analysis included unpaired t-tests and chisquare tests.
Results:Both groups improved clinically, but Group 1 showed significantly greater reductions in burning sensation (p= 0.020), pain, and CRP levels (p= 0.033). Although intergroup differences in mouth opening were not statistically significant, Group 1 showed greater improvement over time. Fibrotic band distribution remained unchanged in both groups. No complications were reported with HBOT.
Conclusion:HBOT provides enhanced symptomatic relief and anti-inflammatory effects in early-stage OSMF when used alongside conventional therapy. While it may not reverse fibrosis, its safety and noninvasive nature support its role in multimodal OSMF management.
